📰 Single dose of ‘magic mushrooms’ provides 5 years of depression relief, researchers find
A new study presented at the Psychedelic Science 2025 conference in Denver revealed that psilocybin, the main psychoactive ingredient in magic mushrooms, could provide relief from depression for up to five years after just one dose. The study followed up with patients diagnosed with major depressive disorder who had participated in a 2020 psilocybin treatment trial, with most reporting lasting improvements in depression symptoms. Previous research suggested the potential of psilocybin as an antidepressant, leading to the first-ever randomized clinical trial in 2020 involving 24 patients. The recent study aimed to explore the long-term effects of psilocybin treatment on 21 original trial participants, with 67% reporting remission from depression five years later. While experts acknowledge the need for more rigorous studies, they are cautiously optimistic about the extended efficacy of psilocybin treatments for mental health conditions.
Psilocybin has shown promise as a potential treatment for post-partum depression, with studies indicating its ability to foster a sense of reconnection in new mothers, potentially improving mood and maternal sensitivity towards infants. The Cleveland Clinic is conducting a study on single-dosing psilocybin for post-partum depression using a proprietary drug similar to psilocybin. Experts emphasize the importance of administering psychedelics in a safe setting under medical supervision to mitigate potential risks like anxiety and hallucinations. Dr. Marc Siegel, a clinical professor of medicine, highlights the therapeutic potential of psychedelics when carefully studied and managed by medical experts, cautioning against unregulated recreational use.
📰 Experimental drug helps patients lose nearly a quarter of body weight in early trials
An experimental weight-loss medication called amycretin, developed by Novo Nordisk, has shown promising results in early-stage trials by helping participants lose up to 24.3% of their body weight. The drug works by replicating hunger hormones amylin and GLP-1 to regulate appetite and boost insulin secretion. Participants who received weekly injections of amycretin lost more weight compared to those who took a placebo, with the highest doses leading to significant weight loss. The oral version of amycretin also showed positive results in reducing body weight. People taking amycretin did not experience a weight-loss plateau, indicating potential for further weight reduction with extended treatment. Common side effects of amycretin include gastrointestinal symptoms like nausea, vomiting, and decreased appetite, which were generally mild to moderate in severity. Novo Nordisk plans to advance both subcutaneous and oral versions of amycretin into phase 3 development for weight management, acknowledging the need for further studies to evaluate long-term benefits and risks.
📰 Simple daily activity could reduce risk of lower back pain, study finds
A new study suggests that taking longer walks could help improve chronic low back pain. Researchers in Norway found that walking for more than 100 minutes per day can reduce the risk of lower back pain by 23% compared to walking less than 78 minutes per day. The study, published in JAMA Network Open, involved over 11,000 participants over the age of 20 who reported instances of back pain lasting three months or longer in the past year. Walking volume was found to have a more significant impact on reducing back pain risk than walking intensity. Dr. Arthur L. Jenkins III, a neurosurgeon, supports the idea of promoting walking to reduce chronic lower back pain, emphasizing the importance of proper posture and engaging core muscles while walking.
📰 Diabetic patients taking GLP-1s may face increased risk of eye disease, study suggests
The article discusses how diabetes is the leading cause of vision loss in people aged 18-64, emphasizing the importance of controlling blood sugar levels to prevent this. The use of GLP-1 receptor agonists like Ozempic and Mounjaro for diabetes and obesity treatment has been linked to potential eye problems, particularly neovascular age-related macular degeneration (nAMD). A Canadian study involving over 139,000 diabetic patients found that those taking GLP-1s had twice the risk of developing nAMD compared to those not taking the medications. The research suggests a dose-response relationship, indicating that longer exposure to these medications may increase the risk of eye issues. While the absolute risk of nAMD remains small, patients on GLP-1 drugs should be vigilant for symptoms like blurred vision and seek medical attention promptly for early detection and treatment.
📰 Dental experts reveal 6 essential tips to prevent tooth loss in aging adults
The article discusses the importance of preventing tooth loss and maintaining good oral health, especially in older adults. It highlights that losing teeth is not inevitable and provides tips from dental professionals to prevent tooth loss and improve overall health. Gum disease is a common issue among older adults and can lead to various health problems, including dementia. Early prevention through regular dental visits, proper oral hygiene practices, and addressing dry mouth is recommended. Financial barriers to dental care and the impact of smoking on tooth loss are also discussed. Additionally, the article emphasizes the importance of personalized dental care and seeking professional advice for oral health treatments like whitening.
0개의 댓글